Dyne Therapeutics, Inc. Shareholders' Equity
Dyne Therapeutics, Inc. (DYN) had Shareholders' Equity of $702.15 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-29
- 2026-06-30: Stockholders' Equity Attributable to Parent $702.15M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $865.05M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $972.13M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $691.78M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $702.15M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $865.05M 10-Q · filed 2026-07-29 |
| 2025-12-31 | $972.13M 10-Q · filed 2026-07-29 |
| 2025-09-30 | $691.78M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $571.45M 10-Q · filed 2026-07-29 |
| 2025-03-31 | $668.97M 10-Q · filed 2026-07-29 |
| 2024-12-31 | $629.84M 10-Q · filed 2026-07-29 |
| 2024-09-30 | $705.54M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $775.19M 10-Q · filed 2025-11-05 |
| 2024-03-31 | $478.06M 10-Q · filed 2025-11-05 |
| 2023-12-31 | $91.29M 10-K · filed 2026-03-02 |
| 2023-09-30 | $152.04M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $206.88M 10-Q · filed 2024-11-12 |
| 2023-03-31 | $241.94M 10-Q · filed 2024-11-12 |
| 2022-12-31 | $252.36M 10-K · filed 2026-03-02 |
| 2022-09-30 | $249.74M 10-Q · filed 2023-10-30 |
| 2022-06-30 | $287.06M 10-Q · filed 2023-10-30 |
| 2022-03-31 | $336.46M 10-Q · filed 2023-10-30 |
| 2021-12-31 | $368.20M 10-K · filed 2025-02-27 |
| 2021-09-30 | $414.12M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $452.60M 10-Q · filed 2022-11-03 |
| 2021-03-31 | $478.26M 10-Q · filed 2022-11-03 |
| 2020-12-31 | $342.37M 10-K · filed 2023-03-02 |
| 2020-09-30 | $366.85M 10-Q · filed 2021-11-04 |
| 2020-06-30 | -$719.00K 10-Q · filed 2021-11-04 |
| 2020-03-31 | $8.19M 10-Q · filed 2021-11-04 |
| 2019-12-31 | $14.04M 10-K · filed 2022-03-10 |
| 2019-09-30 | $19.43M 10-Q · filed 2020-11-05 |
| 2019-06-30 | -$8.46M 10-Q · filed 2020-11-05 |
| 2019-03-31 | -$6.96M 10-Q · filed 2020-11-05 |
| 2018-12-31 | -$4.88M 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |